French contrast agent developer Guerbet in March released financial results for 1998, which the company characterized as a rebuilding year. Guerbet enjoyed slightly higher revenues for the period, posting sales of FFr 1.15 billion ($187.5 million), up 3%
French contrast agent developer Guerbet in March released financial results for 1998, which the company characterized as a rebuilding year. Guerbet enjoyed slightly higher revenues for the period, posting sales of FFr 1.15 billion ($187.5 million), up 3% compared with FFr 1.12 billion ($182.3 million) in 1997. But the companys bottom line swung into the red, with Guerbet recording a net loss of $10.8 million, compared with a net profit of $10.7 million the prior year.
Guerbet embarked on a stringent restructuring program in 1998 to counter increased competition and price pressures in its primary markets, which are mainly x-ray contrast media. The restructuring included a 10% workforce cut. Guerbet said that it expects to return to profitability in 1999.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.